2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Adrenergic Receptor
  5. α adrenergic receptor Isoform
  6. α adrenergic receptor Ligand

α adrenergic receptor Ligand

α adrenergic receptor Ligands (4):

Cat. No. Product Name Effect Purity
  • HY-101390
    (+)-Niguldipine hydrochloride
    		Ligand 98.06%
    (+)-Niguldipine hydrochloride is a 1,4-DHP receptor ligand associated with L-type Ca2+ channels (with Ki values of 85 pmol/L in guinea pig skeletal muscle, 140 pmol/L in brain, and 45 pmol/L in heart) as well as an α1-adrenergic receptor ligand (with a Ki value of 78 nmol/L). (+)-Niguldipine hydrochloride shows much higher binding selectivity for α1α-adrenergic receptors than for α1B-adrenergic receptors. (+)-Niguldipine hydrochloride can be used in studies related to hypertension.
  • HY-W741575
    Iloperidone carboxylic acid
    		Ligand 99.6%
    Iloperidone carboxylic acid (P95-12113) is the metabolite of Iloperidone (HY-17410). Iloperidone carboxylic acid exhibits good affinity for 5-HT2A receptor with pKi of 8.15, and moderate affinity for adrenergic receptor α1/α2B/α2C.
  • HY-181878
    Z8779877149
    		Ligand
    Z8779877149 (Z7149) is a blood-brain barrier-permeable multi-target ligand that targets SERT (Ki=198 nM), α2A adrenergic receptor (Ki=180 nM; EC50=440 nM) and 5-HT2A receptor (EC50=172 nM, Emax=76%). Z8779877149 inhibits 5-HT reuptake and activates Gi and Gq protein signaling pathways, respectively. Z8779877149 effectively alleviates pain responses as well as depression- and anxiety-like behaviors, while exhibiting favorable safety without inducing sedation or motor impairment. Z8779877149 is available for the research of pain, depression and anxiety disorders.
  • HY-176060
    Platelet aggregation-IN-3
    		Ligand
    Platelet aggregation-IN-3 (Compound 5) is a ligand for H2 histamine receptors, α2(A,C)-adrenergic receptors (α2-AR), and 5-HT2(B,C) serotonin receptors. Platelet aggregation-IN-3 can inhibit platelet aggregation induced by ADP and collagen and can also modulate tumour cell-induced platelet aggregation (TCIPA). Platelet aggregation-IN-3 is promising for research of antiplatelet therapy in cardiovascular diseases and the prevention of cancer-related thrombosis and tumour metastasis.